IP50-12: An Indirect Treatment Comparison (ITC) of Nogapendekin Alfa Inbakicept-pmln plus Bacillus Calmette–Guérin (NAI+BCG) and TAR-200 in patients with BCG-unresponsive, Non-Muscle Invasive Bladder Cancer CIS ± Papillary (NMIBC).

IP50-12: An Indirect Treatment Comparison (ITC) of Nogapendekin Alfa Inbakicept-pmln plus Bacillus Calmette–Guérin (NAI+BCG) and TAR-200 in patients with BCG-unresponsive, Non-Muscle Invasive Bladder Cancer CIS ± Papillary (NMIBC).

Sunday, May 17, 2026 7:00 AM to 9:00 AM · 1 hr. 59 min. (America/New_York)
146A
Abstract

Registered attendees

Scott Flanders
Scott Flanders
VP of Medical AffairsImmunityBio, Inc.

Log in

See all the content and easy-to-use features by logging in or registering!